Lipoprotein-Associated Phospholipase A2 Is Related to Plaque Stability and Is a Potential Biomarker for Acute Coronary Syndrome.
10.3349/ymj.2014.55.6.1507
- Author:
Hyemoon CHUNG
1
;
Hyuck Moon KWON
;
Jong Youn KIM
;
Young Won YOON
;
Jihyuk RHEE
;
Eui Young CHOI
;
Pil Ki MIN
;
Bum Kee HONG
;
Se Joong RIM
;
Ji Hyun YOON
;
Sung Joo LEE
;
Jong Kwan PARK
;
Myung Hyun KIM
;
Minhee JO
;
Jeong Hee YANG
;
Byoung Kwon LEE
Author Information
1. Cardiology Division, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. cardiobk@yuhs.ac
- Publication Type:Original Article ; Comparative Study ; Evaluation Studies ; Research Support, Non-U.S. Gov't
- Keywords:
Lp-PLA2;
acute coronary syndrome;
biomarker;
coronary atherosclerotic plaque instability
- MeSH:
1-Alkyl-2-acetylglycerophosphocholine Esterase/*blood;
Acute Coronary Syndrome/*blood/physiopathology;
Aged;
Aged, 80 and over;
Angina Pectoris;
Biological Markers/blood;
C-Reactive Protein/*metabolism;
Coronary Angiography;
Female;
Humans;
Lipoproteins, LDL/*blood;
Logistic Models;
Male;
Middle Aged;
Multivariate Analysis;
Plaque, Atherosclerotic/blood;
ROC Curve;
Risk Factors
- From:Yonsei Medical Journal
2014;55(6):1507-1515
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) binds to low-density lipoprotein. The levels of Lp-PLA2 reflect the plaque burden, and are upregulated in acute coronary syndrome (ACS). We investigated the diagnostic value of Lp-PLA2 levels and found that it might be a potential biomarker for ACS. MATERIALS AND METHODS: We classified 226 study participants into three groups: patients without significant stenosis (control group), patients with significant stenosis with stable angina (SA group), and patients with ACS (ACS group). RESULTS: Lp-PLA2 and high-sensitivity C-reactive protein (hs-CRP) levels were significantly greater in the ACS group than in the SA group (p=0.044 and p=0.029, respectively). Multivariate logistic regression analysis revealed that Lp-PLA2 levels are significantly associated with ACS (odds ratio=1.047, p=0.013). The addition of Lp-PLA2 to the ACS model significantly increased the global chi2 value over traditional risk factors (28.14 to 35.602, p=0.006). The area under the receiver operating characteristic curve for Lp-PLA2 was 0.624 (p=0.004). The addition of Lp-PLA2 level to serum hs-CRP concentration yielded an integrated discrimination improvement of 0.0368 (p=0.0093, standard error: 0.0142) and improved the ability to diagnose ACS. CONCLUSION: Lp-PLA2 levels are related to plaque stability and might be a diagnostic biomarker for ACS.
